Geron Corporation

GERN

$1.12

Name : Geron Corporation

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $718,503,488.00

EPSttm : -0.11

Geron Corporation

$1.12

0.88%

$0.01

GERN — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

11.18

Margin Of Safety %

Put/Call OI Ratio

0.38

EPS Next Q Diff

0.01

EPS Last/This Y

0.11

EPS This/Next Y

Price

1.12

Target Price

3.4

Analyst Recom

Performance Q

-31.29

Upside

-412.5%

Beta

0.63

Ticker: GERN

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-05-11	GERN	1.39	0.44	0.03	52960
2026-05-12	GERN	1.4	0.44	0.15	53354
2026-05-13	GERN	1.415	0.44	0.01	53194
2026-05-14	GERN	1.405	0.44	0.18	53339
2026-05-15	GERN	1.295	0.44	0.16	53549
2026-05-18	GERN	1.235	0.44	0.03	51166
2026-05-19	GERN	1.25	0.43	0.04	51596
2026-05-20	GERN	1.26	0.43	0.02	51334
2026-05-21	GERN	1.265	0.43	0.00	51679
2026-05-22	GERN	1.285	0.42	0.30	52821
2026-05-26	GERN	1.295	0.42	0.01	52956
2026-05-27	GERN	1.265	0.42	0.15	52901
2026-05-28	GERN	1.25	0.42	0.04	52969
2026-05-29	GERN	1.24	0.42	0.45	53110
2026-06-02	GERN	1.165	0.42	0.15	53527
2026-06-03	GERN	1.155	0.41	0.09	54501
2026-06-04	GERN	1.2	0.40	0.34	55770
2026-06-05	GERN	1.175	0.40	0.06	56811
2026-06-08	GERN	1.125	0.40	0.18	56879
2026-06-09	GERN	1.11	0.38	0.01	56125
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-05-11	GERN	1.39	50.0	35.8	-0.02
2026-05-12	GERN	1.40	50.0	35.8	-0.02
2026-05-13	GERN	1.42	50.0	35.8	-0.02
2026-05-14	GERN	1.40	50.0	35.8	-0.02
2026-05-15	GERN	1.29	50.0	35.8	-0.02
2026-05-18	GERN	1.24	-	35.8	-0.02
2026-05-19	GERN	1.23	-	35.8	-0.02
2026-05-20	GERN	1.26	-	35.8	-0.02
2026-05-21	GERN	1.26	-	35.8	-0.02
2026-05-22	GERN	1.28	-	35.8	-0.02
2026-05-26	GERN	1.29	-	35.8	-0.02
2026-05-27	GERN	1.26	-	35.8	-0.02
2026-05-28	GERN	1.25	-	35.8	-0.02
2026-05-29	GERN	1.24	-	35.8	-0.02
2026-06-01	GERN	1.22	-	35.8	-0.02
2026-06-02	GERN	1.16	-	35.8	-0.02
2026-06-03	GERN	1.15	-	35.8	-0.02
2026-06-04	GERN	1.20	-	35.8	-0.02
2026-06-05	GERN	1.17	-	35.8	-0.02
2026-06-08	GERN	1.12	-	35.8	-0.02
2026-06-09	GERN	1.12	-	35.8	-0.02
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-05-11	GERN	-0.03	-5.22	13.49
2026-05-12	GERN	-0.03	-5.22	12.43
2026-05-13	GERN	-0.03	-5.22	12.43
2026-05-14	GERN	-0.03	-5.22	12.43
2026-05-15	GERN	-0.03	-5.22	12.43
2026-05-18	GERN	-0.03	-5.23	12.43
2026-05-19	GERN	-0.03	-5.23	12.43
2026-05-20	GERN	-0.03	-5.23	12.43
2026-05-21	GERN	-0.03	-5.23	12.06
2026-05-22	GERN	-0.07	-5.23	12.06
2026-05-26	GERN	-0.07	-0.68	12.06
2026-05-27	GERN	-0.07	-0.68	12.06
2026-05-28	GERN	-0.07	-0.68	11.18
2026-05-29	GERN	-0.07	-0.68	11.18
2026-06-02	GERN	-0.07	-0.63	11.18
2026-06-03	GERN	-0.07	-0.63	11.18
2026-06-04	GERN	-0.07	-0.63	11.18
2026-06-05	GERN	-0.07	-0.63	11.18
2026-06-08	GERN	-0.07	-0.60	11.18
2026-06-09	GERN	-0.07	-0.60	11.18
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.01

Avg. EPS Est. Current Quarter

-0.01

Avg. EPS Est. Next Quarter

-0.01

Insider Transactions

-0.07

Institutional Transactions

-0.6

Beta

0.63

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

79.1

Max Drawdown 5-Year %

-79

Target Price

3.4

P/E

Forward P/E

17.23

PEG

P/S

3.66

P/B

3.13

P/Free Cash Flow

EPS

-0.1

Average EPS Est. Cur. Y

-0.02

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-35.48

Relative Volume

0.82

Return on Equity vs Sector %

-56.9

Return on Equity vs Industry %

-40.7

EPS 1 7Days Diff

EPS 1 30Days Diff

0.02

EBIT Estimation

35.8

◆ GERN Healthcare

$1.12

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

20/20

Pullback

13/25

Volume

7/15

Valuation

15/20

TP/AR

1/10

Options

7/10

RSI

28.8

Range 1M

4.3%

Sup Dist

1.5%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

14/25

Growth

27/30

Estimates

2/20

Inst/Vol

0/15

Options

10/10

EPS Yr

82.1%

EPS NY

378.6%

52W%

8.8%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +132.2% upside

Quality

6/30

Valuation

18/30

Growth

20/25

Stability

4/10

LT Trend

4/5

Upside

+132.2%

Quality

Geron Corporation

Sector: Healthcare

Industry: Biotechnology

Employees: 258

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

GERN

Latest News

—

Caricamento notizie per GERN…

stock quote shares GERN – Geron Corporation Stock Price stock today

news today GERN – Geron Corporation stock forecast ,stock prediction 2023 2024 2025

marketwatch GERN – Geron Corporation yahoo finance google finance

stock history GERN – Geron Corporation invest stock market

stock prices GERN premarket after hours

ticker GERN fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: GERN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y